

ASX RELEASE

3 June 2024

AMPLIA ESTABLISHES WORLD CLASS CLINICAL ADVISORY BOARD

HIGHLIGHTS

- *Five experienced oncologists and drug development professionals have been appointed to Amplia's Clinical Advisory Board to guide international clinical trial design and development strategy*

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce the appointment of five key opinion leaders and clinical oncologists to its Clinical Advisory Board (CAB).

The CAB will provide expert clinical insight and strategic advice with a particular focus on pancreatic cancer to Amplia as the Company prepares to undertake clinical trials in the United States.

The CAB will be chaired by Amplia's long-standing clinical advisor, Dr Jose Iglesias, who has over 30 years' experience in clinical development of new oncology drugs. Dr Iglesias, who was responsible for the Phase 3 development of Abraxane® in pancreatic cancer, has commented "I am excited to be working with Amplia to advance their clinical trial program in pancreatic cancer. Narmafotinib, is a promising new drug for a devastating and poorly managed disease, greatly in need of new treatment options."

Joining Dr Iglesias on the Clinical Advisory Board are leading experts in oncology and drug development, Dr Jordan Berlin, (Vanderbilt-Ingram Cancer Center, Nashville, USA), Dr Mitesh Borad (Mayo Clinic, Phoenix, USA), Prof. Nick Pavlakis (North Shore Private Hospital, Sydney), and Dr Jason Lickliter (Nucleus Network, Melbourne). Further details about each member of the Clinical Advisory Board can be found on our website www.ampliatx.com.

Amplia CEO and Managing Director Dr Chris Burns commented: "We are delighted to have convened this distinguished panel of experts. Each member brings a depth of experience that will greatly benefit both the development of narmafotinib in pancreatic cancer, and the company more broadly as our clinical strategy matures. This is a significant milestone in the Company's growth."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](#) (@ampliatx), [Threads](#) (@ampliatx) and [LinkedIn](#).